Advertisement


Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary

2023 ASCO Annual Meeting

Advertisement

Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve diversity in breast and lung cancer trials, and mediators of racial and ethnic inequities in clinical trial participation among U.S. patients with cancer from 2011 to 2022 (Abstracts 6509, 6510, 6511).



Related Videos

Lymphoma

Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease

Jennifer L. Crombie, MD, of Dana-Farber Cancer Institute, discusses the historically poor outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Her study examined real-world data on the use of novel therapies in this population and found that outcomes with second- and third-line regimens of polatuzumab vedotin-piiq plus bendamustine and rituximab and tafasitamab plus lenalidomide remain suboptimal, with worse outcomes particularly after chimeric antigen receptor T-cell therapy (Abstract 7552).

Kidney Cancer
Immunotherapy

Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib

Rana R. McKay, MD, of the University of California, San Diego, and Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center, discuss the 5-year follow-up results with the combination of a checkpoint inhibitor plus a VEGFR tyrosine kinase inhibitor as first-line treatment for patients with advanced clear cell renal cell carcinoma (RCC). Pembrolizumab plus axitinib continued to demonstrate improved survival outcomes as well as overall response rate vs sunitinib for patients with previously untreated disease (Abstract LBA4501).

Gynecologic Cancers

Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Mansoor R. Mirza, MD, of Denmark’s Rigshospitalet and Copenhagen University Hospital, discuss new findings on dostarlimab-gxly plus carboplatin/paclitaxel, which improved progression-free survival while maintaining health-related quality of life, further supporting its use as a standard of care in primary advanced or recurrent endometrial cancer (Abstract 5504).

Gynecologic Cancers

Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection

Marie Plante, MD, of Canada’s Université Laval and the CHUQ Hotel Dieu de Québec, discusses phase III results from a study that compared radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. The pelvic recurrence rate at 3 years in the women who underwent simple hysterectomy is not inferior to those who had radical hysterectomy. In addition, fewer surgical complications and better quality of life were observed with simple hysterectomy (LBA5511).

Kidney Cancer

Rana R. McKay, MD, and Toni K. Choueiri, MD, on RCC: New Findings on Efficacy and Safety of Atezolizumab Plus Cabozantinib

Rana R. McKay, MD, of the University of California, San Diego, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discuss results from the phase III CONTACT-03 study, showing that, for patients with metastatic renal cell carcinoma (RCC), adding the PD-L1 inhibitor atezolizumab to cabozantinib did not improve clinical outcomes compared with treatment with cabozantinib alone. In addition, higher toxicities were observed in the combination arm (Abstract LBA4500).

Advertisement

Advertisement




Advertisement